11. Myasthenia gravis Clinical trials / Disease details


Clinical trials : 315 Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-000895-40-DK
(EUCTR)
28/03/201926/02/2019Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia GravisBeta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis - BETA-MG Myasthenia Gravis
MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Salbutamol WZF 4 mg
INN or Proposed INN: Salbutamol
Other descriptive name: SALBUTAMOL SULFATE PH. EUR.
Aarhus University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 3Denmark
2ChiCTR1800017696
2016-07-012018-08-10Effect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia GravisEffect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia Gravis Myasthenia GravisGroup A:Magnesium Sulfate;Group B:Normal saline;The University of Hong Kong-Shenzhen HospitalNULLRecruiting1860BothGroup A:30;Group B:30;China